The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes.
Cardiovascular disease is the major cause of morbidity and mortality associated with diabetes. There is increasing evidence that advanced glycation endproducts (AGEs) play a pivotal role in atherosclerosis, in particular in diabetes. AGE accumulation is a measure of cumulative metabolic and oxidative stress, and may so represent the "metabolic memory". Furthermore, increased AGE accumulation is closely related to the development of cardiovascular complications in diabetes. This review article will focus on the clinical relevance of measuring AGE accumulation in diabetic patients by focusing on AGE formation, AGEs as predictors of long-term complications, and interventions against AGEs.
Meerwaldt
Robbert
R
Department of Surgery, Isala Clinics, Zwolle, The Netherlands. r.meerwaldt@isala.nl
Links
Thera
T
Zeebregts
Clark
C
Tio
Rene
R
Hillebrands
Jan-Luuk
JL
Smit
Andries
A
D000818:Animals; D015415:Biomarkers / Q000097:blood; D002318:Cardiovascular Diseases / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control; D048909:Diabetes Complications / Q000209:etiology* / Q000378:metabolism / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000188:drug therapy / Q000378:metabolism*; D017127:Glycation End Products, Advanced / Q000037:antagonists & inhibitors / Q000097:blood*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D008833:Microcirculation / Q000378:metabolism
D015415:Biomarkers; D017127:Glycation End Products, Advanced; D007004:Hypoglycemic Agents